Logo image of LRMR

LARIMAR THERAPEUTICS INC (LRMR) Stock Fundamental Analysis

NASDAQ:LRMR - Nasdaq - US5171251003 - Common Stock - Currency: USD

3.19  -0.08 (-2.45%)

After market: 3.1722 -0.02 (-0.56%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LRMR. LRMR was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LRMR as it has an excellent financial health rating, but there are worries on the profitability. LRMR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LRMR had negative earnings in the past year.
LRMR had a negative operating cash flow in the past year.
In the past 5 years LRMR always reported negative net income.
In the past 5 years LRMR always reported negative operating cash flow.
LRMR Yearly Net Income VS EBIT VS OCF VS FCFLRMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

LRMR has a Return On Assets of -29.57%. This is in the better half of the industry: LRMR outperforms 69.09% of its industry peers.
LRMR's Return On Equity of -32.65% is fine compared to the rest of the industry. LRMR outperforms 76.91% of its industry peers.
Industry RankSector Rank
ROA -29.57%
ROE -32.65%
ROIC N/A
ROA(3y)-43.61%
ROA(5y)-45.54%
ROE(3y)-51.91%
ROE(5y)-57.56%
ROIC(3y)N/A
ROIC(5y)N/A
LRMR Yearly ROA, ROE, ROICLRMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

LRMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LRMR Yearly Profit, Operating, Gross MarginsLRMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for LRMR has been increased compared to 1 year ago.
Compared to 5 years ago, LRMR has more shares outstanding
There is no outstanding debt for LRMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LRMR Yearly Shares OutstandingLRMR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
LRMR Yearly Total Debt VS Total AssetsLRMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 4.35 indicates that LRMR is not in any danger for bankruptcy at the moment.
LRMR has a better Altman-Z score (4.35) than 79.22% of its industry peers.
LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.35
ROIC/WACCN/A
WACCN/A
LRMR Yearly LT Debt VS Equity VS FCFLRMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

LRMR has a Current Ratio of 13.10. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.10, LRMR belongs to the top of the industry, outperforming 85.61% of the companies in the same industry.
A Quick Ratio of 13.10 indicates that LRMR has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 13.10, LRMR belongs to the best of the industry, outperforming 85.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.1
Quick Ratio 13.1
LRMR Yearly Current Assets VS Current LiabilitesLRMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for LRMR have decreased strongly by -51.32% in the last year.
EPS 1Y (TTM)-51.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.46% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-43.27%
EPS Next 2Y-40.04%
EPS Next 3Y-34.06%
EPS Next 5Y11.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LRMR Yearly Revenue VS EstimatesLRMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
LRMR Yearly EPS VS EstimatesLRMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LRMR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LRMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LRMR Price Earnings VS Forward Price EarningsLRMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LRMR Per share dataLRMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

LRMR's earnings are expected to decrease with -34.06% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-40.04%
EPS Next 3Y-34.06%

More info and screens

0

5. Dividend

5.1 Amount

LRMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (2/21/2025, 8:00:00 PM)

After market: 3.1722 -0.02 (-0.56%)

3.19

-0.08 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)03-12 2025-03-12/amc
Inst Owners105.27%
Inst Owner Change-99.5%
Ins Owners1.65%
Ins Owner Change4.28%
Market Cap203.55M
Analysts88.89
Price Target21.61 (577.43%)
Short Float %8.09%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.04%
Min EPS beat(2)-9.17%
Max EPS beat(2)37.25%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-18.88%
Max EPS beat(4)37.25%
EPS beat(8)5
Avg EPS beat(8)9.19%
EPS beat(12)9
Avg EPS beat(12)12.02%
EPS beat(16)10
Avg EPS beat(16)5.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.48%
PT rev (3m)-3.28%
EPS NQ rev (1m)-2.81%
EPS NQ rev (3m)-2.81%
EPS NY rev (1m)1.84%
EPS NY rev (3m)-2.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS3.11
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.57%
ROE -32.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.61%
ROA(5y)-45.54%
ROE(3y)-51.91%
ROE(5y)-57.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 155.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.1
Quick Ratio 13.1
Altman-Z 4.35
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.33%
Cap/Depr(5y)102.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-43.27%
EPS Next 2Y-40.04%
EPS Next 3Y-34.06%
EPS Next 5Y11.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-101.57%
EBIT Next 3Y-51.37%
EBIT Next 5Y29.81%
FCF growth 1Y-103.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.23%
OCF growth 3YN/A
OCF growth 5YN/A